Contrasting Alpha Tau Medical (NASDAQ:DRTS) & Anika Therapeutics (NASDAQ:ANIK)
Contrasting Alpha Tau Medical (NASDAQ:DRTS) & Anika Therapeutics (NASDAQ:ANIK)
Anika Therapeutics (NASDAQ:ANIK – Get Rating) and Alpha Tau Medical (NASDAQ:DRTS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
安妮卡治療(納斯達克：ANIK-GET評級)和阿爾法頭醫療(納斯達克：DRTS-GET評級)都是小盤醫療公司，但哪隻股票更具優勢？我們將根據這兩家公司的分析師建議、機構持股、股息、風險、收益、盈利能力和估值的強弱對它們進行比較。
Insider & Institutional Ownership
內部人與機構所有權
91.6% of Anika Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Alpha Tau Medical shares are held by institutional investors. 3.0% of Anika Therapeutics shares are held by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
安妮卡治療公司91.6%的股份由機構投資者持有。相比之下，Alpha Tau Medical 1.0%的股份由機構投資者持有。安妮卡治療公司3.0%的股份由公司內部人士持有。相比之下，Alpha Tau Medical 39.5%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、大型基金管理公司和對衝基金相信，一家公司的長期表現將好於大盤。
Profitability
盈利能力
This table compares Anika Therapeutics and Alpha Tau Medical's net margins, return on equity and return on assets.
此表比較了Anika Treeutics和Alpha Tau Medical的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Anika Therapeutics | -10.33% | -2.49% | -2.05% |
| Alpha Tau Medical | N/A | -49.72% | -33.76% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 安妮卡治療公司 | -10.33% | -2.49% | -2.05% |
| Alpha Tau醫療公司 | 不適用 | -49.72% | -33.76% |
Analyst Ratings
分析師評級
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anika Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
| Alpha Tau Medical | 0 | 0 | 3 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 安妮卡治療公司 | 0 | 1 | 1 | 0 | 2.50 |
| Alpha Tau醫療公司 | 0 | 0 | 3 | 0 | 3.00 |
Anika Therapeutics currently has a consensus target price of $28.50, suggesting a potential downside of 7.05%. Alpha Tau Medical has a consensus target price of $17.67, suggesting a potential upside of 338.38%. Given Alpha Tau Medical's stronger consensus rating and higher possible upside, analysts clearly believe Alpha Tau Medical is more favorable than Anika Therapeutics.
Anika Treateutics目前的共識目標價為28.50美元，暗示潛在下行7.05%。Alpha Tau Medical的共識目標價為17.67美元，暗示潛在上漲338.38%。鑑於Alpha Tau Medical更強的共識評級和更高的可能上行空間，分析師顯然認為Alpha Tau Medical比Anika Treeutics更有利。
Risk & Volatility
風險與波動性
Anika Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Anika Treateutics的貝塔係數為0.97，表明其股價的波動性比標準普爾500指數低3%。相比之下，Alpha Tau Medical的貝塔係數為0.81，這表明其股價的波動性比標準普爾500指數低19%。
Earnings & Valuation
收益與估值
This table compares Anika Therapeutics and Alpha Tau Medical's revenue, earnings per share and valuation.
此表比較了Anika Treeutics和Alpha Tau Medical的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anika Therapeutics | $147.79 million | 3.03 | $4.13 million | ($1.09) | -28.13 |
| Alpha Tau Medical | N/A | N/A | -$27.27 million | N/A | N/A |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 安妮卡治療公司 | 1.4779億美元 | 3.03 | 413萬美元 | ($1.09) | -28.13 |
| Alpha Tau醫療公司 | 不適用 | 不適用 | -2,727萬元 | 不適用 | 不適用 |
Anika Therapeutics has higher revenue and earnings than Alpha Tau Medical.
Anika Treateutics的收入和收益高於Alpha Tau Medical。
Summary
摘要
Anika Therapeutics beats Alpha Tau Medical on 6 of the 11 factors compared between the two stocks.
在兩隻股票之間的11個因素中，Anika Treeutics在6個因素上擊敗了Alpha Tau Medical。
About Anika Therapeutics
關於Anika Treateutics
(Get Rating)
(獲取評級)
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Anika Treateutics，Inc.是一家聯合保護公司，在美國、歐洲和國際上創造和提供骨關節炎(OA)疼痛管理、再生解決方案、軟組織修復和骨保護關節技術領域的早期介入整形外科護理的進步。該公司開發、製造和商業化基於透明質酸(HA)技術平臺的產品。它的OA疼痛管理產品系列包括Monovisc、Orthovisc、Cingal和Hyvisc，這些產品被證明可以緩解骨關節炎的疼痛；關節保存和修復產品系列包括大約150個骨保存關節技術產品組合、一系列運動醫學軟組織修復解決方案和整形外科再生解決方案產品。該公司的非整形外科產品系列包括用於非整形外科應用的基於HA的產品，包括粘連屏障產品、高級傷口護理產品、眼科產品以及耳、鼻和喉產品。安妮卡治療公司成立於1983年，總部設在馬薩諸塞州的貝德福德。
About Alpha Tau Medical
關於Alpha Tau Medical
(Get Rating)
(獲取評級)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Alpha Tau醫療有限公司是一家臨牀階段的腫瘤治療公司，在以色列和美國從事用於治療實體癌症的擴散阿爾法放射療法(Alpha DART)的研究、開發和商業化。其Alpha-DART技術用於皮膚癌、口腔癌、胰腺癌和乳腺癌的臨牀試驗；以及肝細胞癌、多形性膠質母細胞瘤、肺癌等的臨牀前研究。該公司成立於2015年，總部設在以色列耶路撒冷。
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Anika治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Anika Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。